Table 2.

Estimated population PK–PD parameters of maraviroc in healthy volunteers and HIV-positive patients

Parameters		Symbols	Estimate	SE (CV%)	IIV (CV%)	IOV (CV%)
F1 3 mg		θ1	0.139	18
F1 10 mg		θ2	0.166	12
F1 25 mg		θ3	0.265	16
F1 100 mg			1.00	–
F1 300 mg		θ4	2.27	17
F1 600 mg		θ5	2.50	12
ALAG1	(h)	θ6	0.01	21	>100
Ka	(h−1)	θ7	1.14	7.6	89	60
K 3 mg	(h−1)	θ8	0.104	6.5
K 10 mg	(h−1)	θ9	0.117	3.8
K 25 mg	(h−1)	θ10	0.129	6.2
K 100 mg	(h−1)	θ11	0.288	5.7
K 300 mg	(h−1)	θ12	0.358	5.2
K 600 mg	(h−1)	θ13	0.376	4.7
V2	(l)	θ14	754	9.5	31
K23	(h−1)	θ15	0.074	6.7	24
K32	(h−1)	θ16	0.051	2.2
Emax	%	θ17	66.8	2.4
KD	(ng ml−1)	θ18	0.0894	13	21
E0	%	θ19	24.9	6	28
EPS1*	CV(%)		38	6.5
EPS2†	(%)		11	9.3

^*Multiplicative error model.

^†Additive error model. IIV, interindividual variability; IOV, interoccasion variability.